Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Kidney Injury, Acute
Interventions: Sodium Nitrate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more

Conditions: Gastrointestinal Health
Interventions: Bovine Colostrum - Lower Dose, Bovine Colostrum - Higher Dose, Placebo; Dietary Supplement
Lead sponsor: Bovita Labs, LLC; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis of the Knee
Interventions: Lidoderm (Lidocaine 5% Patch), Placebo Patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 37 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Paradise Valley, Arizona • Phoenix, Arizona • Milford, Connecticut + 16 more

Conditions: Gut -Microbiota, Inflammation Biomarkers, Pain Assessment, Joint Pain
Interventions: Wild blueberry, Placebo; Dietary Supplement
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 40 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Pain
Interventions: OMT vs. Ibruprofen; Other
Lead sponsor: St. Joseph's Regional Medical Center, New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Paterson, New Jersey

Conditions: Spondyloarthritis
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more

Conditions: Osteoarthritis
Interventions: GSK3196165, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Avonex (Interferon beta 1a), Riluzole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Docetaxel, Imatinib mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Covid-19 Prevention
Interventions: Ad26.COV2.S, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more

Conditions: Psoriasis
Interventions: MEDI-522, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more

Conditions: Heart Failure, Congestive, Dyspnea, Pulmonary Edema
Interventions: Nesiritide; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Herpes Zoster
Interventions: Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, placebo, sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more

Conditions: Ovarian Cancer, Breast Cancer
Interventions: Essiac; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cognitive Disorders
Interventions: SUVN-D4010, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Musculoskeletal Pain
Interventions: Vitamin D 2, Vitamin D2 Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: SYN-010 21 mg, SYN-010 42 mg, Placebo; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dyslipidemia
Interventions: BMS-823778, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more

Conditions: Major Depressive Disorder, Alcohol Use Disorder
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hydrocortisone, Depression, Healthy Volunteers
Interventions: Hydrocortisone Oral, Placebo Oral Tablet; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19
Interventions: Citicoline, Saline/Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Colostrum and Gut Health

Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee

Dietary Wild Blueberries and Joint Health

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

OMT vs. Standard Therapy in the Management of Acute Neck and Low Back Pain in the Emergency Department

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

A Study of Ad26.COV2.S in Adults (COVID-19)

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Vitamin D to ENhance TraUma REcovery

A Study of the Effect of SYN-010 on Subjects With IBS-C

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

Exploring the Effects of Corticosteroids on the Human Hippocampus

Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)